Skip to content

Study · Randomized controlled trial · n = 15 · 2016

9 results

Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial.

Ilkowitz JT, Katikaneni R, Cantwell M, Ramchandani N, Heptulla RA

Journal of diabetes science and technology22 Aug 2016Cited by 29 (Europe PMC)

PMID27184690 (opens in a new tab)PMCIDPMC5032955 (opens in a new tab)DOI10.1177/1932296816647976 (opens in a new tab)PepBankPUB-27184690
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes on a closed-loop system, adjunct liraglutide lowered average blood glucose versus insulin monotherapy.

    In plain wordsIn adults with type 1 diabetes using a closed-loop system, adding liraglutide lowered average blood glucose compared with insulin alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean blood glucose, 8:00 pm to 9:00 pm next day
    Study

    n = 15

    Comparator
    Insulin monotherapy in the closed-loop system
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg · subcutaneousAs given in this study (human).

    Measurements

    Average blood glucose
    144.6 mg/dl
    liraglutide arm
    Average blood glucose
    159.7 mg/dl
    insulin monotherapy arm

    Source sentences

    Summary
    The average BG levels from 8:00 pm (day 1) to 9:00 pm (day 2) were lower in the liraglutide arm (144.6 ± 36.31 vs 159.7 ± 50.88 mg/dl respectively; P = .0002).
    2 context sentences
    Summary · context
    The liraglutide arm was associated with overall decreased mean BG levels (P = .0002).
    Summary · context
    This was a randomized, controlled, open-label, crossover design trial comparing insulin monotherapy versus adjuvant subcutaneous liraglutide 1.2 mg and insulin, using the CL system in 15 patients.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes on a closed-loop system, two-hour postbreakfast and lunch blood glucose profiles were better with liraglutide than with insulin alone.

    In plain wordsIn adults with type 1 diabetes using a closed-loop system, glucose after breakfast and lunch was better with liraglutide than with insulin alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseTwo-hour postbreakfast and lunch blood glucose profiles
    Study

    n = 15

    Comparator
    Insulin monotherapy in the closed-loop system
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Two-hour postbreakfast and lunch BG profiles were better in the liraglutide arm (P < .05)
    1 context sentence
    Summary · context
    This was a randomized, controlled, open-label, crossover design trial comparing insulin monotherapy versus adjuvant subcutaneous liraglutide 1.2 mg and insulin, using the CL system in 15 patients.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes on a closed-loop system, the 2-hour postbreakfast blood glucose AUC differed significantly between liraglutide and insulin alone.

    In plain wordsIn adults with type 1 diabetes using a closed-loop system, glucose after breakfast differed significantly between liraglutide and insulin alone.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedTwo-hour postbreakfast blood glucose AUC
    Study

    n = 15

    Comparator
    Insulin monotherapy in the closed-loop system
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Postprandially, the area under the curve (AUC) for 2-hour postbreakfast and lunch BG levels were significant (P = .01, P = .03)
    1 context sentence
    Summary · context
    This was a randomized, controlled, open-label, crossover design trial comparing insulin monotherapy versus adjuvant subcutaneous liraglutide 1.2 mg and insulin, using the CL system in 15 patients.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes on a closed-loop system, the 2-hour postlunch blood glucose AUC differed significantly between liraglutide and insulin alone.

    In plain wordsIn adults with type 1 diabetes using a closed-loop system, glucose after lunch differed significantly between liraglutide and insulin alone.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedTwo-hour postlunch blood glucose AUC
    Study

    n = 15

    Comparator
    Insulin monotherapy in the closed-loop system
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Postprandially, the area under the curve (AUC) for 2-hour postbreakfast and lunch BG levels were significant (P = .01, P = .03)
    1 context sentence
    Summary · context
    This was a randomized, controlled, open-label, crossover design trial comparing insulin monotherapy versus adjuvant subcutaneous liraglutide 1.2 mg and insulin, using the CL system in 15 patients.
  5. 05HumanRandomized controlled trialMechanism

    In adults with type 1 diabetes on a closed-loop system, the postbreakfast glucagon AUC differed significantly between liraglutide and insulin alone.

    In plain wordsIn adults with type 1 diabetes using a closed-loop system, glucagon after breakfast differed significantly between liraglutide and insulin alone.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedPostbreakfast glucagon AUC
    Study

    n = 15

    Comparator
    Insulin monotherapy in the closed-loop system
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    1.2 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    and the AUC for glucagon, postbreakfast (P < .0001) and lunch (P < .05), was also significant.
    1 context sentence
    Summary · context
    This was a randomized, controlled, open-label, crossover design trial comparing insulin monotherapy versus adjuvant subcutaneous liraglutide 1.2 mg and insulin, using the CL system in 15 patients.
  6. 06HumanRandomized controlled trialMechanism

    In adults with type 1 diabetes on a closed-loop system, the postlunch glucagon AUC differed significantly between liraglutide and insulin alone.

    In plain wordsIn adults with type 1 diabetes using a closed-loop system, glucagon after lunch differed significantly between liraglutide and insulin alone.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedPostlunch glucagon AUC
    Study

    n = 15

    Comparator
    Insulin monotherapy in the closed-loop system
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    1.2 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    and the AUC for glucagon, postbreakfast (P < .0001) and lunch (P < .05), was also significant.
    1 context sentence
    Summary · context
    This was a randomized, controlled, open-label, crossover design trial comparing insulin monotherapy versus adjuvant subcutaneous liraglutide 1.2 mg and insulin, using the CL system in 15 patients.
  7. 07HumanRandomized controlled trialMechanism

    In adults with type 1 diabetes on a closed-loop system, insulin assay values were lower with liraglutide than with insulin alone.

    In plain wordsIn adults with type 1 diabetes using a closed-loop system, insulin levels were lower with liraglutide than with insulin alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseInsulin assay values
    Study

    n = 15

    Comparator
    Insulin monotherapy in the closed-loop system
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    1.2 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    the insulin and glucagon assay values were lower (P < .0001)
    1 context sentence
    Summary · context
    This was a randomized, controlled, open-label, crossover design trial comparing insulin monotherapy versus adjuvant subcutaneous liraglutide 1.2 mg and insulin, using the CL system in 15 patients.
  8. 08HumanRandomized controlled trialMechanism

    In adults with type 1 diabetes on a closed-loop system, glucagon assay values were lower with liraglutide than with insulin alone.

    In plain wordsIn adults with type 1 diabetes using a closed-loop system, glucagon levels were lower with liraglutide than with insulin alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlucagon assay values
    Study

    n = 15

    Comparator
    Insulin monotherapy in the closed-loop system
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    1.2 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    the insulin and glucagon assay values were lower (P < .0001)
    1 context sentence
    Summary · context
    This was a randomized, controlled, open-label, crossover design trial comparing insulin monotherapy versus adjuvant subcutaneous liraglutide 1.2 mg and insulin, using the CL system in 15 patients.
  9. 09HumanRandomized controlled trialSafety outcome

    In adults with type 1 diabetes on a closed-loop system, the incidence of hypoglycemia did not differ between the liraglutide and insulin-only arms.

    In plain wordsIn adults with type 1 diabetes using a closed-loop system, low blood sugar was no more common with liraglutide than with insulin alone.

    Peptide
    Liraglutide
    Outcome
    No significant changeIncidence of hypoglycemia
    Study

    n = 15

    Comparator
    Insulin monotherapy in the closed-loop system
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    1.2 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The incidence of hypoglycemia did not differ between arms (P = .83, Fisher's exact test).
    1 context sentence
    Summary · context
    This was a randomized, controlled, open-label, crossover design trial comparing insulin monotherapy versus adjuvant subcutaneous liraglutide 1.2 mg and insulin, using the CL system in 15 patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.